MAPS 2025

MAPS 2025 Decoded: The Medical Affairs Playbook for Successful Drug Launches

At the MAPS Americas 2025 conference in New Orleans, one of the pivotal discussions centered around preparing for drug launches in the current pharmaceutical landscape. While many important topics were covered, a critical element that was notably missing from the discussion was the need for a strategic north star—a guiding philosophy that ensures all tactical…...
Read More

Top Stories

DIA MASC 2025

Medical Affairs 2.0: GenAI as the Catalyst for

Digital and AI were hot topics underpinning many of the...
Biopharma 2025 Trends

Biopharma Trends 2025: 3 Things to Know Right Now

The global business climate is ever-evolving, and 2025 looks...

The Paradigm Shift from Traditional Scientific

In the rapidly evolving biopharma landscape, the approach to...
Leverage Social Media to Transform Medical Affairs | Promoting Disease Awareness, Ensuring Compliance and Assessing Outcomes

Leveraging Social Media to Transform Medical Affairs

This whitepaper explores the role of social media in enhancing Medical Affairs functions. As digital...

Transforming Scientific Content with Microsoft 365 Copilot: Cactus Life Sciences in the Spotlight

We are thrilled to announce that Cactus Life Sciences has been featured in Microsoft Stories...

Launch Excellence: The Path Forward for Medical Affairs

Learn how Medical Affairs can redefine launch excellence by streamlining the journey from clinical trial...
HEOR Pharma Payers

Didactic to Dynamic: Innovative Approaches to Deeper Payer Engagements

HEOR is a fast-evolving field. Feedback from payers can influence research plans and help create...

From Transactional to Transformational: Bringing Patient Centricity to the Next Level

The pharma industry’s focus is shifting from the transactional approach to a transformational approach by...
Stakeholder perspectives on digital scientific content

Digital Scientific Content: Stakeholder Perspectives

What do the different relevant stakeholder groups truly expect from pharma-generated scientific content?...

Learn more ABOUT our company.